Novo Nordisk A/S and Eli Lilly and Co welcome heavy bullish news! It is rumored that weight loss drugs may enter the U.S. medical insurance system.
According to reports, the government led by usa President Biden is proposing a regulation that would require payment for weight loss drugs, potentially expanding access to these medications for millions of obese americans and creating a massive new medical bill for elected President Donald Trump.
Eli Lilly and Co (LLY.US) cancels double injections, brewing super BD for muscle gain and fat loss.
GLP-1 dual heroes Semaglutide and Tirzepatide, the total sales in 2024 will exceed $40 billion, leading to a huge demand in the muscle-building drug market.
Is weight loss medication including in usa medical insurance, becoming the strongest 'roadblock' for the Trump team?
"Weight loss duo" leads significant increase.
Hong Kong stocks move | Laika Pharmaceutical-B (02105) rose more than 11% in early trading. Overnight, U.S. stocks in the weight loss drugs sector experienced a broad rise. The company has launched clinical cooperation with eli lilly and co on a new weigh
Lai Kai Pharmaceutical-B (02105) rose more than 11% in the morning, as of the time of publication, it increased by 9.79%, reaching 17.04 Hong Kong dollars, with a turnover of 30.7419 million Hong Kong dollars.
Futu Morning Report | The US stock market party continues! The s&p 500 index has risen for seven consecutive days, setting a new historical high; Federal Reserve meeting minutes: future interest rate cuts will be cautious, and the end of monetary easing i
Market response to Trump's tariff threats: auto stocks wail, the Canadian dollar hits a four-year low, and the Mexican peso plunges nearly 3%; dell technologies drops over 10% after hours, with total net revenue for the third quarter at 24.37 billion USD, below analyst expectations.
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert